Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains

Li Chen, Mengmeng Sun, Huajun Zhang, Xinghai Zhang, Yanfeng Yao, Ming Li, Kangyin Li, Pengfei Fan, Haiwei Zhang, Ye Qin, Zhe Zhang, Entao Li, Zhen Chen, Wuxiang Guan, Shanshan Li, Changming Yu (), Kaiming Zhang (), Rui Gong () and Sandra Chiu ()
Additional contact information
Li Chen: Chinese Academy of Sciences
Mengmeng Sun: University of Science and Technology of China
Huajun Zhang: Chinese Academy of Sciences
Xinghai Zhang: Chinese Academy of Sciences
Yanfeng Yao: Chinese Academy of Sciences
Ming Li: University of Science and Technology of China
Kangyin Li: Chinese Academy of Sciences
Pengfei Fan: Beijing Institute of Biotechnology
Haiwei Zhang: Chinese Academy of Sciences
Ye Qin: Chinese Academy of Sciences
Zhe Zhang: Chinese Academy of Sciences
Entao Li: University of Science and Technology of China
Zhen Chen: Chinese Academy of Sciences
Wuxiang Guan: Chinese Academy of Sciences
Shanshan Li: University of Science and Technology of China
Changming Yu: Beijing Institute of Biotechnology
Kaiming Zhang: University of Science and Technology of China
Rui Gong: Chinese Academy of Sciences
Sandra Chiu: University of Science and Technology of China

Nature Communications, 2024, vol. 15, issue 1, 1-14

Abstract: Abstract Nipah virus (NiV) is a World Health Organization priority pathogen and there are currently no approved drugs for clinical immunotherapy. Through the use of a naïve human phage-displayed Fab library, two neutralizing antibodies (NiV41 and NiV42) targeting the NiV receptor binding protein (RBP) were identified. Following affinity maturation, antibodies derived from NiV41 display cross-reactivity against both NiV and Hendra virus (HeV), whereas the antibody based on NiV42 is only specific to NiV. Results of immunogenetic analysis reveal a correlation between the maturation of antibodies and their antiviral activity. In vivo testing of NiV41 and its mature form (41-6) show protective efficacy against a lethal NiV challenge in hamsters. Furthermore, a 2.88 Å Cryo-EM structure of the tetrameric RBP and antibody complex demonstrates that 41-6 blocks the receptor binding interface. These findings can be beneficial for the development of antiviral drugs and the design of vaccines with broad spectrum against henipaviruses.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-47213-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47213-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-47213-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().